var data={"title":"Acenocoumarol (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Acenocoumarol (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/46022?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=acenocoumarol-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Acenocoumarol (United States: Not available): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854980\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sintrom</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854984\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Vitamin K Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855019\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage must be individualized. The following information is based on the manufacturer's labeling in Canada.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention/treatment of thrombosis/embolism: </b> Oral: Initial: 8 to 12 mg on day 1, followed by 4 to 8 mg on day 2. Subsequent dosage should be based on INR measurements. Usual range of maintenance doses: 1 to 10 mg/day. Tapering of dosage is recommended prior to discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525054\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution; lower dosages may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12851253\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\"> Use with caution; the manufacturer's labeling does not provide specific dosing recommendations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12851252\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution; the manufacturer's labeling does not provide specific dosing recommendations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950003\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sintrom: 1 mg, 4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11215944\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855021\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer at the same time each day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854985\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders; atrial fibrillation with risk of embolism; adjunct in the treatment of coronary occlusion and transient ischemic attacks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855004\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Interferes with hepatic synthesis of vitamin K-dependent coagulation factors (II, VII, IX, X)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854994\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-top:0em;display:inline\">As with all anticoagulants, bleeding is the major adverse effect of acenocoumarol. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the intensity of anticoagulation and patient susceptibility. Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic:  Skin necrosis (including hemorrhagic forms) (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Priapism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemorrhage may occur at virtually any site that may be predisposed to bleeding. Includes cerebral hemorrhage, gallbladder hemorrhage, hematuria, hemophthalmos, hepatic hemorrhage, melena, menorrhagia, metrorrhagia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854990\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to acenocoumarol, related coumarin derivatives, or any component of the formulation; hemorrhagic tendencies and/or blood dyscrasias (eg, hemophilia, thrombocytopenic purpura, leukemia); recent or potential surgery of the eye or CNS; major regional lumbar block anesthesia or surgery resulting in large, open surfaces; bleeding from the GI, respiratory, or GU tract; aneurysm (cerebral or dissecting aortic); cerebrovascular hemorrhage; recent surgical procedures resulting in increased fibrinolytic activity (eg, surgery of the lung, prostate, uterus); polyarthritis; severe hypertension; severe parenchymal lesions of the liver and kidneys; pericarditis or pericardial effusion; subacute bacterial endocarditis; ascorbic acid deficiency; uncooperative patient (eg, alcoholic, unsupervised senile, or psychotic) intramuscular injections; inadequate laboratory facilities; threatened abortion; eclampsia/pre-eclampsia; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854991\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity: May cause hypersensitivity reactions, including anaphylaxis; use with caution in patients with anaphylactic disorders. Cross-reactivity among coumarin anticoagulants has been described.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding: May cause major or fatal bleeding. Risk factors for bleeding include high intensity anticoagulation (INR &gt;4), age (&gt;65 years), variable INRs, history of GI bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, severe diabetes, malignancy, trauma, renal insufficiency, polycythemia vera, vasculitis, open wound, history of PUD, indwelling catheters, menstruating and postpartum women, drug-drug interactions and long duration of therapy or known genetic deficiency in CYP2C9 activity. Patient must be instructed to report bleeding, accidents, or falls as well as any new or discontinued medications, herbal or alternative products used, significant changes in smoking or dietary habits. Unrecognized bleeding sites (eg, colon cancer) may be uncovered by anticoagulation. Treatment should be withdrawn at the earliest signs of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin necrosis/gangrene: Necrosis or gangrene of the skin and other tissues can occur (rarely) due to early hypercoagulability; risk is increased in patients with protein C or S deficiency. Onset is usually within the first few days of therapy and is frequently localized to the limbs, breast, or penis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; &quot;Purple toe&rdquo; syndrome:  &quot;Purple toe&rdquo; syndrome, due to cholesterol microembolization, has been described with coumarin-type anticoagulants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dietary insufficiency: Use with caution in patients with prolonged dietary insufficiencies (vitamin K deficiency).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infection: Use with caution in patients with acute infection or active TB; antibiotics and fever may alter response to acenocoumarol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment (undergoes hepatic metabolism).  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: Use with caution in patients with thyroid disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: The elderly may be more sensitive to anticoagulant therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ovulating women: May be at risk of developing ovarian hemorrhage at the time of ovulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Patients with genomic variants in CYP2C9 and/or VKORC1: Presence of the CYP2C9*3 allele and/or polymorphism of the vitamin K oxidoreductase (VKORC1) gene may increase the risk of bleeding. Lower doses may be required in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Patient selection: Use care in the selection of patients appropriate for this treatment; ensure patient cooperation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855003\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2C19 (minor), CYP2C9 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855002\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9159&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: May enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with daily acetaminophen doses exceeding 1.3 or 2 g/day for multiple consecutive days.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May decrease the serum concentration of Vitamin K Antagonists. More specifically, this effect has been described in heavy drinking alcoholic patients (over 250 g alcohol daily for over 3 months).  The role of alcohol itself is unclear.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists. Management: Monitor patients extra closely for evidence of increased anticoagulant effects if amiodarone is started.  Consider empiric reduction of 30% to 50% in warfarin dose, though no specific guidelines on dose adjustment have been published.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amorolfine: May enhance the anticoagulant effect of Acenocoumarol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral NS5B RNA Polymerase Inhibitors: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithyroid Agents: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Vitamin K Antagonists. Management: Monitor INR more closely. An anticoagulant dose increase may be needed after a barbiturate is initiated or given at an increased dose. Anticoagulant dose decreases may be needed following barbiturate discontinuation or dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bicalutamide: May increase the serum concentration of Vitamin K Antagonists. Specifically, free concentrations of the vitamin K antagonists may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May increase the metabolism of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: May increase the serum concentration of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Vitamin K Antagonists. Management: Monitor for decreased INR and effects of vitamin K antagonists if carbamazepine is initiated/dose increased, or increased INR and effects if carbamazepine is discontinued/dose decreased. Warfarin dose adjustments will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chenodiol: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Hydrate: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol (Systemic) may increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists. Cloxacillin may enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coenzyme Q-10: May diminish the anticoagulant effect of Vitamin K Antagonists. Coenzyme Q-10 may enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cranberry: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inducers (Moderate): May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desvenlafaxine: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dicloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Econazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Vitamin K Antagonists. Efavirenz may increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Ophthalmic): May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esomeprazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): May diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethacrynic Acid: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethotoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Ethotoin. Management: Anticoagulant dose adjustment will likely be necessary when ethotoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide Phosphate: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Exenatide: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fat Emulsion (Fish Oil and Plant Based): May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenugreek: May enhance the anticoagulant effect of Vitamin K Antagonists. Management: Seek alternatives to fenugreek in patients receiving vitamin K antagonists. Monitor patients receiving these combinations closely for increases in INR and systemic effects of the vitamin K antagonist (particularly easy bruising and bleeding).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists. Flucloxacillin may decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Systemic): May increase the serum concentration of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Topical): May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Fosphenytoin. Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of Vitamin K Antagonists. Management: Vitamin K antagonist dose adjustments may be required when used with systemic fusidic acid.  Patients using this combination should be monitored extra closely for evidence of bleeding and to determine appropriate dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ginkgo Biloba: May enhance the adverse/toxic effect of Vitamin K Antagonists. Management: Consider avoiding the use of this combination of agents. Monitor for signs and symptoms of bleeding if vitamin K antagonists and Ginkgo biloba are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glutethimide: May increase the metabolism of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Green Tea: May enhance the adverse/toxic effect of Acenocoumarol. Particularly, the risk of bleeding may be increased due to possible antiplatelet effects of green tea. Green Tea may diminish the anticoagulant effect of Acenocoumarol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Griseofulvin: May decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): May enhance the anticoagulant effect of Vitamin K Antagonists.<b> Exceptions: </b>AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivermectin (Systemic): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lansoprazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: May enhance the anticoagulant effect of Vitamin K Antagonists. Leflunomide may diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LevOCARNitine: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levomilnacipran: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Vitamin K Antagonists.<b> Exceptions: </b>Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Menadiol Diphosphate: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Menatetrenone: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): May increase the serum concentration of Vitamin K Antagonists. Management: Consider alternatives to concomitant therapy with these agents.  If concomitant therapy cannot be avoided, consider reducing the dose of the vitamin K antagonist and monitor for increased INR/bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miconazole (Topical): May increase the serum concentration of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Milnacipran: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the anticoagulant effect of Vitamin K Antagonists. Multivitamins/Minerals (with ADEK, Folate, Iron) may diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nafcillin: May diminish the anticoagulant effect of Vitamin K Antagonists. Management: Consider choosing an alternative antibiotic. Monitor for decreased therapeutic effects and need for dose adjustments of oral anticoagulants if nafcillin is initiated/dose increased, or increased effects if nafcillin is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neomycin: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Vitamin K Antagonists. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omeprazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oritavancin: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May enhance the anticoagulant effect of Vitamin K Antagonists.<b> Exceptions: </b>Dicloxacillin; Nafcillin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Phenytoin. Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phytonadione: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): May diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products. Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: May enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with higher doses (equivalent to acetaminophen doses exceeding 1.3 to 2 g/day) for multiple consecutive days.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May enhance the anticoagulant effect of Vitamin K Antagonists. Note that the INR/PT might be unchanged in the face of increased bleeding.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May increase the metabolism of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Vitamin K Antagonists.<b> Exceptions: </b>Salsalate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May increase the metabolism of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Streptokinase: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists. Management: Administer vitamin K antagonists at least 2 hours before or at least 6 hours after sucralfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: May decrease the metabolism of Vitamin K Antagonists. Sulfinpyrazone may decrease the protein binding of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonamide Antibiotics: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: May increase the serum concentration of Vitamin K Antagonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: May increase the serum concentration of Vitamin K Antagonists. Management: Monitor INR and signs/symptoms of bleeding closely when starting or stopping this combination.  Anticoagulant dose adjustment will likely be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toremifene: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venlafaxine: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorinostat: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zafirlukast: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855007\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethanol: Acute ethanol ingestion (binge drinking) decreases the metabolism of oral anticoagulants and increases PT/INR. Chronic daily ethanol use increases the metabolism of oral anticoagulants and decreases PT/INR. Management: Avoid ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: Vitamin K can reverse the anticoagulation effects of acenocoumarol; large amounts of food high in vitamin K (such as beef liver, pork liver, green tea, and green leafy vegetables) may reverse acenocoumarol, decrease prothrombin time, and lead to therapeutic failure. Management: Patients should not change dietary habits once stabilized on acenocoumarol therapy. A balanced diet with a consistent intake of vitamin K is essential. High doses of vitamin A, E, or C may alter PT. Cranberry juice or other cranberry products may increase the INR in patients receiving a similar agent (warfarin) and cause severe bleeding (flavonoids found in cranberries may inhibit cytochrome P450 isoenzyme CYP2C9 which metabolize warfarin).  Similar risks might be anticipated with acenocoumarol as it also undergoes CYP2C9 metabolism. Management: Use caution with fish oils or omega-3 fatty acids; cranberry juice or other cranberry products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854986\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Acenocoumarol crosses the placenta. Teratogenic effects have been reported with coumarin derivative anticoagulants following first trimester exposure and may include coumarin embryopathy (nasal hypoplasia and/or stippled epiphyses; limb hypoplasia may also be present).  Adverse events to the fetus have also been observed following second and third trimester exposure with coumarin derivative anticoagulants and may include CNS abnormalities (including ventral midline dysplasia, dorsal midline dysplasia). Fatal hemorrhage in the fetus has been reported even when the mother&rsquo;s acenocoumarol levels were in the therapeutic range. Acenocoumarol should not be used during pregnancy because of significant risks. Women of childbearing potential are advised to use effective contraception during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12850980\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Very small quantities of acenocoumarol can be detected in breast milk and undesirable effects in nursing infants are not anticipated. The manufacturer recommends prophylaxis therapy with phytonadione (1 mg administered once weekly) and monitoring of the infant for signs of bleeding. The American College of Chest Physicians (ACCP) considers acenocoumarol to be safe to use in breast-feeding women (Guyatt,  2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855020\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Foods high in vitamin K (eg, beef liver, pork liver, green tea, and leafy green vegetables) inhibit anticoagulant effect. Do not change dietary habits once stabilized on acenocoumarol therapy. A balanced diet with a consistent intake of vitamin K is essential. Avoid large amounts of alfalfa, asparagus, broccoli, Brussels sprouts, cabbage, cauliflower, green teas, kale, lettuce, spinach, turnip greens, watercress; these decrease efficacy of oral anticoagulants. It is recommended that an adult diet contain a  <b>consistent </b> vitamin K content of 75-120 mcg/day. Check with healthcare provider before changing diet. Avoid using multivitamins that contain vitamin K.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855023\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">PT/INR (<b>Note:</b> To obtain a valid PT in patients receiving heparin, allow 4 to 5 hours after last IV dose and 12 to 24 hours after last SubQ dose before blood is drawn); hepatic function, CBC</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855261\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Hepatic synthesis of coagulation factors II, VII, IX, and X, as well as proteins C and S, requires the presence of vitamin K. These clotting factors are biologically activated by the addition of carboxyl groups to key glutamic acid residues within the proteins&rsquo; structure. In the process, &ldquo;active&rdquo; vitamin K is oxidatively converted to an &ldquo;inactive&rdquo; form, which is then subsequently reactivated by vitamin K epoxide reductase complex 1 (VKORC1). Coumarins are thought to inhibit VKORC1, thus depleting functional vitamin K reserves and hence reduce synthesis of active clotting factors. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855011\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Peak anticoagulant effect: Oral: 36-48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:  0.16-0.34 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, via oxidation: R-enantiomer (by CYP2C9 [primary], 1A2, and 2C19; S-enantiomer primarily by CYP2C9) and via keto-reduction to inactive metabolites; also undergoes nitro-reduction via gut flora. (Thijssen, 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 60%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: R-enantiomer: ~11 hours; S-enantiomer: &lt;2 hours (Thijssen, 1986) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1-3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (60% as metabolites; minimal amount as unchanged drug); feces (29% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869446\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acenox (CL);</li>\n      <li>Acitrom (IN);</li>\n      <li>Coarol (CL);</li>\n      <li>Neo-Sintrom (CL);</li>\n      <li>Nistrom (IN);</li>\n      <li>Sinkumar (UA);</li>\n      <li>Sinthrome (GB);</li>\n      <li>Sintrom (AR, AT, BE, BG, CH, ES, FR, GR, IL, IT, JO, LB, LU, MX, PT, PY, RO, SI, VN);</li>\n      <li>Syncumar (HN, RU);</li>\n      <li>Venohem (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Armstrong MJ, Gronseth G, Anderson DC, et al. Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology.</i> 2013;80(22):2065-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acenocoumarol-united-states-not-available-drug-information/abstract-text/23713086/pubmed\" target=\"_blank\" id=\"23713086\">23713086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baillargeon J, Holmes HM, Lin YL, et al. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. <i>Am J Med.</i> 2012;125(2):183-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acenocoumarol-united-states-not-available-drug-information/abstract-text/22269622/pubmed\" target=\"_blank\" id=\"22269622\">22269622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acenocoumarol-united-states-not-available-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karsli ED, Erdogan &Ouml;, Esen E, et al. Comparison of the effects of warfarin and heparin on bleeding caused by dental extraction: A clinical study. <i>J Oral Maxillofac Surg.</i> 2011;69(10):2500-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acenocoumarol-united-states-not-available-drug-information/abstract-text/21764203/pubmed\" target=\"_blank\" id=\"21764203\">21764203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sintrom (acenocoumarol) tablets [prescribing information]. Montreal, Canada: Paladin Labs Inc; May 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suvarna R, Pirmohamed M, and Henderson L, &ldquo;Possible Interaction Between Warfarin and Cranberry Juice,&rdquo; <i>BMJ</i>, 2003, 327(7429):1454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acenocoumarol-united-states-not-available-drug-information/abstract-text/14684645/pubmed\" target=\"_blank\" id=\"14684645\">14684645</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    T&agrave;ssies D, Freire C, Pijoan J, et al, &ldquo;Pharmacogenetics of Acenocoumarol: Cytochrome P450 CYP 2C9 Polymorphisms Influence Dose Requirements and Stability of Anticoagulation,&rdquo; <i>Haematologica</i>, 2002, 87(11):1185-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acenocoumarol-united-states-not-available-drug-information/abstract-text/12414349/pubmed\" target=\"_blank\" id=\"12414349\">12414349</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teichert M, van Schaik RH, Hofman A, et al, &ldquo;Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period,&rdquo; <i>Clin Pharmacol Ther</i>, 2009, 85(4):379-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acenocoumarol-united-states-not-available-drug-information/abstract-text/19225451/pubmed\" target=\"_blank\" id=\"19225451\">19225451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thijssen HH, Janssen GM, and Baars LG, &ldquo;Lack of Effect of Cimetidine on Pharmacodynamics and Kinetics of Single Oral Doses of R- and S-Acenocoumarol,&rdquo; <i>Eur J Clin Pharmacol</i>, 1986, 30(5):619-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acenocoumarol-united-states-not-available-drug-information/abstract-text/3758150/pubmed\" target=\"_blank\" id=\"3758150\">3758150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thijssen HH, Flinois JP, and Beaune PH, &ldquo;Cytochrome P4502C9 is the Principal Catalyst of Racemic Acenocoumarol Hydroxylation Reactions in Human Liver Microsomes,&rdquo; <i>Drug Metab Dispos</i>, 2000, 28(11):1284-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acenocoumarol-united-states-not-available-drug-information/abstract-text/11038154/pubmed\" target=\"_blank\" id=\"11038154\">11038154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Touloupidis S, Zoumpos I, Kalaitzis C, et al, &ldquo;Acenocoumarol Associated Priapism: Report of a Case,&rdquo; <i>Andrologia</i>, 2004, 36(1):47-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acenocoumarol-united-states-not-available-drug-information/abstract-text/14871265/pubmed\" target=\"_blank\" id=\"14871265\">14871265</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9159 Version 155.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F854980\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F854984\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F855019\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2525054\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F12851253\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F12851252\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950003\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11215944\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F855021\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F854985\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F855004\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F854994\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F854990\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F854991\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F855003\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F855002\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F855007\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F854986\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F12850980\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F855020\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F855023\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F855261\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F855011\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869446\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9159|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=acenocoumarol-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Acenocoumarol (United States: Not available): Patient drug information \t</a></li></ul></div></div>","javascript":null}